Published in Brain Pathol on October 01, 2002
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A (2003) 7.57
Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J Biol Chem (2009) 4.90
Pesticides and Parkinson's disease--is there a link? Environ Health Perspect (2006) 2.01
Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Brain Pathol (2003) 1.75
Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. Autophagy (2008) 1.74
The PINK1/Parkin pathway: a mitochondrial quality control system? J Bioenerg Biomembr (2009) 1.72
A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease. Hum Mol Genet (2010) 1.41
6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic Biol Med (2007) 1.32
Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp Cell Res (2008) 1.29
Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration. Eur J Neurosci (2011) 1.24
Pink1 regulates the oxidative phosphorylation machinery via mitochondrial fission. Proc Natl Acad Sci U S A (2011) 1.24
Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains. J Biol Chem (2005) 1.19
Apoptosis inducing factor mediates caspase-independent 1-methyl-4-phenylpyridinium toxicity in dopaminergic cells. J Neurochem (2005) 1.16
Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis. J Bioenerg Biomembr (2009) 1.11
Tickled PINK1: mitochondrial homeostasis and autophagy in recessive Parkinsonism. Biochim Biophys Acta (2009) 1.09
Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics (2005) 1.09
HGF-, EGF-, and dexamethasone-induced gene expression patterns during formation of tissue in hepatic organoid cultures. Gene Expr (2003) 1.08
Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. BMC Neurosci (2010) 1.01
Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. Mitochondrion (2009) 0.98
Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis (2007) 0.95
Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease. Curr Bioact Compd (2008) 0.94
Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease. J Biol Chem (2009) 0.94
Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J Alzheimers Dis (2009) 0.94
Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci (2004) 0.90
Drosophila models of Parkinson's disease: discovering relevant pathways and novel therapeutic strategies. Parkinsons Dis (2011) 0.89
Methamphetamine-induced neurotoxicity linked to ubiquitin-proteasome system dysfunction and autophagy-related changes that can be modulated by protein kinase C delta in dopaminergic neuronal cells. Neuroscience (2012) 0.88
A role for a novel protein, nucleolin, in Parkinson's disease. Neurosci Lett (2009) 0.85
In a flurry of PINK, mitochondrial bioenergetics takes a leading role in Parkinson's disease. EMBO Mol Med (2009) 0.79
The Prevalence and Distribution of Neurodegenerative Compound-Producing Soil Streptomyces spp. Sci Rep (2016) 0.75
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci (2002) 4.15
Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci (2003) 3.30
Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol (2003) 2.85
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis (2002) 2.83
An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci (2002) 2.54
Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci (2007) 2.28
N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci (2008) 2.18
Animal models of Parkinson's disease. Bioessays (2002) 2.05
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem (2001) 1.99
A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis (2009) 1.92
Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis (2006) 1.83
Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem (2010) 1.82
Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci (2003) 1.80
Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci (2003) 1.77
Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem (2005) 1.65
Environment, mitochondria, and Parkinson's disease. Neuroscientist (2002) 1.63
Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem (2005) 1.59
Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol Dis (2005) 1.57
Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp Neurol (2010) 1.56
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol (2002) 1.51
Role of external pallidal segment in primate parkinsonism: comparison of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism and lesions of the external pallidal segment. J Neurosci (2004) 1.48
Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol (2005) 1.47
Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett (2003) 1.46
Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res (2005) 1.45
The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord (2003) 1.44
Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem (2007) 1.44
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis (2006) 1.43
Neurotoxic in vivo models of Parkinson's disease recent advances. Prog Brain Res (2010) 1.41
MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One (2008) 1.39
Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci (2005) 1.38
Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry (2003) 1.33
Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS One (2008) 1.32
The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci (2011) 1.31
Redox cycling of the herbicide paraquat in microglial cultures. Brain Res Mol Brain Res (2005) 1.27
Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Exp Neurol (2007) 1.24
Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis (2009) 1.24
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol (2004) 1.20
Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol (2008) 1.18
Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging (2006) 1.18
Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Sci (2006) 1.17
Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J (2004) 1.13
Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J Neurosci (2011) 1.13
A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol Dis (2009) 1.11
Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem (2010) 1.11
We need something better, and we need it now: fetal striatal transplantation in Huntington's disease? Neurology (2002) 1.10
Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One (2010) 1.08
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem (2006) 1.06
Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem (2006) 1.06
Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. Neurotoxicology (2010) 1.06
In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Arch Biochem Biophys (2003) 1.05
Lessons from the rotenone model of Parkinson's disease. Trends Pharmacol Sci (2010) 1.05
Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radic Biol Med (2013) 1.03
Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med (2013) 1.02
Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chem Res Toxicol (2004) 1.01
Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol (2008) 1.01
Mitochondrial iron metabolism and its role in neurodegeneration. J Alzheimers Dis (2010) 1.01
Paraquat neurotoxicity is mediated by a Bak-dependent mechanism. J Biol Chem (2007) 1.00
Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem (2003) 1.00
Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis (2005) 1.00
Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS One (2013) 0.99
Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther (2007) 0.99
Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol Cell Biochem (2005) 0.99
Protection against oxidant-induced apoptosis by mitochondrial thioredoxin in SH-SY5Y neuroblastoma cells. Toxicol Appl Pharmacol (2006) 0.98
Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid Redox Signal (2011) 0.97
The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods (2005) 0.96
Automated imaging system for fast quantitation of neurons, cell morphology and neurite morphometry in vivo and in vitro. Neurobiol Dis (2012) 0.95
Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol (2006) 0.95
Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models. Neurobiol Dis (2012) 0.94
Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs. J Neurochem (2007) 0.94
Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. J Neurosci Res (2010) 0.94
Hypokinesia and reduced dopamine levels in zebrafish lacking β- and γ1-synucleins. J Biol Chem (2011) 0.94
Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. J Neurochem (2013) 0.93
Oxidative damage in Parkinson's disease. Antioxid Redox Signal (2005) 0.92
A FRET-based method to study protein thiol oxidation in histological preparations. Free Radic Biol Med (2008) 0.91
Toxicity of redox cycling pesticides in primary mesencephalic cultures. Antioxid Redox Signal (2005) 0.90
NeuN is not a reliable marker of dopamine neurons in rat substantia nigra. Neurosci Lett (2009) 0.90
Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim Biophys Acta (2009) 0.90
Neurodegenerative disease: pink, parkin and the brain. Nature (2006) 0.89
Quantitative evaluation of the effects of mitochondrial permeability transition pore modifiers on accumulation of calcium phosphate: comparison of rat liver and brain mitochondria. Arch Biochem Biophys (2004) 0.89
PCR based determination of mitochondrial DNA copy number in multiple species. Methods Mol Biol (2015) 0.88
Pilocapine alters NMDA receptor expression and function in hippocampal neurons: NADPH oxidase and ERK1/2 mechanisms. Neurobiol Dis (2011) 0.88
Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. Biochim Biophys Acta (2012) 0.87
Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease. Exp Neurol (2004) 0.87
Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther (2004) 0.87
Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease. Mov Disord (2011) 0.87
Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Exp Neurol (2004) 0.87
Decreased alpha-synuclein expression in the aging mouse substantia nigra. Exp Neurol (2009) 0.87
Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. J Parkinsons Dis (2011) 0.86
The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol (2007) 0.86
Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp Neurol (2006) 0.86
DJ-1 expression modulates astrocyte-mediated protection against neuronal oxidative stress. J Mol Neurosci (2012) 0.86